Results 11 to 20 of about 13,497 (214)

Glucose-Dependent Insulinotropic Polypeptide [PDF]

open access: yesDiabetes, 2011
OBJECTIVE To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) effects on insulin and glucagon release in 10 healthy male subjects ([means ± SEM] aged 23 ± 1 years, BMI 23 ± 1 kg/m2, and HbA1c 5.5 ± 0.1%).
Mikkel Christensen   +4 more
openaire   +4 more sources

Gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide signaling in adipose tissue [PDF]

open access: yesJournal of Diabetes Investigation, 2019
GIPR signaling in adipose tissue plays an important role in HFD-induced insulin resistance and hepatic steatosis in vivo, with no direct effect on fat accumulation, through IL-6 signaling.
Shunsuke Yamane, Norio Harada
doaj   +3 more sources

Glucose-dependent insulinotropic polypeptide and tissue inflammation: Implications for atherogenic cardiovascular disease

open access: yesEuropean Journal of Inflammation, 2022
Glucose-dependent insulinotropic polypeptide (GIP) has pleiotropic actions on pancreatic endocrine function, adipose tissue lipid metabolism, and skeletal calcium metabolism.
Xiaoming He
doaj   +1 more source

The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism. [PDF]

open access: yesInt J Mol Sci
Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin hormone identified, best known for promoting glucose-stimulated insulin secretion. Increasing evidence has expanded its physiological relevance beyond glucose metabolism, revealing a significant role for GIP in the gut–bone axis.
Lin A   +8 more
europepmc   +3 more sources

The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. [PDF]

open access: yesJ Endocrinol
Adipose tissue was once known as a reservoir for energy storage but is now considered a crucial organ for hormone and energy flux with important effects on health and disease. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted from the small intestinal K cells, responsible for augmenting insulin release, and has gained ...
Kagdi S, Lyons SA, Beaudry JL.
europepmc   +3 more sources

Searching for the physiological role of glucose‐dependent insulinotropic polypeptide [PDF]

open access: yesJournal of Diabetes Investigation, 2016
AbstractGlucose‐dependent insulinotropic polypeptide (GIP) was established as a gut hormone more than 40 years ago, and there is good experimental support for its role as an incretin hormone although deletion of the GIP receptor or the GIP cells or GIP receptor mutations have only minor effects on glucose metabolism.
Holst, Jens Juul   +9 more
openaire   +3 more sources

Expression of glucose-dependent insulinotropic polypeptide in the zebrafish

open access: yesAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
In mammals, glucose-dependent insulinotropic polypeptide (GIP) is synthesized predominately in the small intestine and functions in conjunction with insulin to promote nutrient deposition. However, little is known regarding GIP expression and function in early vertebrates like the zebrafish, a model organism representing an early stage in the ...
Michelle C, Musson   +5 more
openaire   +3 more sources

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease [PDF]

open access: yesReviews in the Neurosciences, 2016
AbstractGlucose-dependent insulinotropic polypeptide (GIP) is a member of the incretin hormones and growth factors. Neurons express the GIP receptor, and GIP and its agonists can pass through the blood brain barrier and show remarkable neuroprotective effects by protecting synapse function and numbers, promoting neuronal proliferation, reducing amyloid
Ji, Chenhui   +4 more
openaire   +2 more sources

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

open access: yesNature Communications, 2020
Both agonism and antagonism of the glucose-dependent insulinotropic polypeptide receptor (GIPR) lead to weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical models.
Elizabeth A. Killion   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy